Novel Fights 'Patient' Claim Rehearing In Suprep Suit
Law360, New York (July 7, 2014, 7:22 PM EDT) -- Generic drug producer Novel Laboratories Inc. urged the Federal Circuit on Thursday to deny Braintree Laboratories Inc.’s bid for an en banc rehearing on the construction of the term “a patient” in its Suprep colon cleanser patent, saying the court properly rendered the claim to mean a “patient population.”
In response to Braintree’s May petition for a panel rehearing, Novel argues that the Federal Circuit correctly ruled that the term “a patient” in U.S. Patent Number 6,946,149 applied to the general class of persons to whom the patent is directed, rather than “one or more” patients.
“Braintree’s construction would, indeed, be...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!